Elsevier

Metabolism

Volume 51, Issue 3, March 2002, Pages 366-371
Metabolism

Acylcarnitine profiles in fibroblasts from patients with respiratory chain defects can resemble those from patients with mitochondrial fatty acid [beta ]-oxidation disorders

https://doi.org/10.1053/meta.2002.30521Get rights and content

Abstract

Mitochondrial fatty acid [beta ]-oxidation (FAO) is coupled to the respiratory chain (RC). Functional defects of one pathway may lead to secondary alteration in flux through the other. We investigated the acylcarnitine profiles in cultured fibroblasts obtained from 14 healthy subjects, 31 patients with 8 different primary enzyme deficiencies of FAO, and 16 patients with primary RC defects including both isolated and multiple enzyme complex defects. Intact cells were incubated in media containing deuterium-labeled hexadecanoic acid and L-carnitine, and the acylcarnitines analysed using an electrospray tandem mass spectrometer. All FAO-deficient cell lines revealed disease-specific acylcarnitine profiles related to the sites of defects. Some cell lines from patients with RC defects showed profiles similar to those of controls, whereas others had abnormal profiles mimicking those found in FAO disorders. The acylcarnitine profiles of patients with RC enzyme defects were not predictable, and in some patients defects caused by mutations in either nuclear-encoded or mitochondrial DNA were associated with acylcarnitine abnormalities. While in vitro acylcarnitine profiling is useful for the diagnosis of FAO deficiencies, abnormal profiles do not exclusively indicate these disorders, and primary defects of the RC remain a possibility. Awareness of this diagnostic pitfall will aid in the selection of subsequent confirmatory tests and therapeutic options.

References (0)

Cited by (52)

  • A novel MT-CO2 variant causing cerebellar ataxia and neuropathy: The role of muscle biopsy in diagnosis and defining pathogenicity

    2021, Neuromuscular Disorders
    Citation Excerpt :

    We identified the accumulation of medium-chain acylcarnitine species in the patient's plasma, similar to the findings reported in other pathogenic MT-CO2 variants [7,15,16], which mimic the findings in patients with primary fatty acid oxidation disorder due to multiple acyl-CoA dehydrogenase deficiency (MADD). Abnormal acylcarnitine profiles in the fibroblasts of patients with mitochondrial respiratory chain deficiencies, resembling patients with various primary fatty acid oxidation defects, were previously reported [25]. More recently, a metabolomics study of nine patients with LRPPRC-related mitochondrial disease (deficiency in this nuclear-encoded mitochondrial protein also causes isolated complex IV deficiency) identified elevated C2, C6, C12, C14, C14:1, C16, C18:1, and C18:2 acylcarnitines, suggesting the perturbation of fatty acid oxidation pathway is likely to be secondary to mitochondrial respiratory chain dysfunction [26].

  • Metabolomics of mitochondrial disease

    2017, Mitochondrion
    Citation Excerpt :

    Although this approach could shed light on the basic biochemistry of the disease, it would have been beneficial from a diagnostic point of view to compare patients suffering from MD to a disease control group, the latter being a group of patients with a different disease but displaying similar clinical symptoms. However, only a few metabolomics studies have used disease control groups, such as organic acidemia and fatty acid oxidation defects, to compare to their mitochondrial disease cohorts (Barshop, 2004; Sim et al., 2002). One of the latest studies involving metabolomics of mitochondrial disease implemented an alternative control group referred to as clinically referred controls (Venter et al., 2015), i.e. individuals who initially presented with symptoms usually associated with mitochondrial disease, but did not display a respiratory chain deficiency on enzymatic level.

View all citing articles on Scopus

Supported in part by the Small Grants Scheme of The Children's Hospital at Westmead, Sydney, Australia.

View full text